Characteristics of metastatic breast cancer patients who survived more than 10 years

Research Square (Research Square)(2022)

引用 0|浏览2
暂无评分
摘要
Abstract Background/Aim: Despite advances in treatment for breast cancer, metastatic breast cancer (MBC) remains difficult to cure, and few MBC patients survive 10 years after receiving a breast cancer metastasis diagnosis. We collected the cases of MBC patients who survived >10 years post-metastasis diagnosis and assessed the patients’ characteristics. Results: We retrospectively analyzed the cases of 245 consecutive patients diagnosed with MBC between January 2005 and December 2012 at our institution. Among them, 167 patients with confirmed survival of >10 years (i.e., long-term survival) or confirmed death at ≤10 years post-metastasis diagnosis were enrolled. There were 22 patients with MBC who survived >10 years. Regarding the cancer subtypes, 11 patients (50%) with long-term survival were HER2-positive. Seven of the 11 patients with HER2-positive MBC have been without recurrence although anti-HER2 therapy was discontinued. Triple-negative breast cancer (TNBC) was most common in the patients who survived ≤5 years, but was not present in the >10-year survival group. In the HER2-negative cases, more cases in the long-term survival group were treated with local therapy (34.4% in the <5-year survival group, 43.8% in the 5–10-year group, and 72.7% in the >10-year group).Conclusion: Our analyses revealed that MBC patients who survive >10 years after being diagnosed with metastasis are more likely to be HER2-positive and more likely to be treated with local therapy. This suggests the efficacy of anti-HER2 therapy, and, conversely, clarifies unmet needs in TNBC and luminal-type MBC. The usefulness of local therapy was also supported by our findings.
更多
查看译文
关键词
metastatic breast cancer patients,metastatic breast cancer,breast cancer patients,breast cancer,cancer patients
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要